Primary Peptides is a pioneer in two transformational areas of therapeutic development:
- Protein-protein interaction blockade which prevents specific disease-causing proteins from interacting with each other
- Protein degradation which harnesses the body's own natural processes to destroy disease causing proteins
By adopting these approaches, we are expanding the scope of new targets for drug development, by unlocking the untapped pool of targets that to date have been considered undruggable. Our goal is to develop a new generation of therapeutics for patients that currently have few options, if any, to treat their diseases effectively.
We are a clinical stage company initially focused in the areas of cardiovascular disease, oncology and neurodegeneration.